BridgeMD
New treatment option for Acute Heart Failure
Official title Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload
ClinicalTrials.gov ID: NCT06166654
What this study is testing
What is Acetazolamide?
Acetazolamide is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for acute heart failure.
Also referred to as Standard of care including loop-diuretics.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Aim to identify the best strategy for treating acute heart failure (AHF) with volume overload, particularly focusing on patients resistant to standard loop-diuretics. The trial is a double-blinded, randomized, controlled, multicenter study.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years
- Acute hospital admission with a clinical diagnosis of acute heart failure with volume overload.
- Display risk of diuretic resistance, characterized by:
- Daily loop-diuretics administration for a minimum of 7 days before admission, or
- Insufficient decongestion observed in the preceding 24 hours (weight reduction \<500g or negative fluid balance \<1L) despite being treated with...
You likely can't join if
- Acute coronary syndrome
- Systolic blood pressure \<85 mmHg
- Use of renal replacement therapy or ultrafiltration in-hospital before study inclusion
- Treatment with acetazolamide or metolazone during the index hospitalization prior to randomization
- Known allergy to any of the used drugs
- Severe hypokalemia (\<2.5 mmol/l) or severe hyponatremia (\<125 mmol/l)
See the full eligibility criteria
- Age ≥ 18 years
- Acute hospital admission with a clinical diagnosis of acute heart failure with volume overload.
- Display risk of diuretic resistance, characterized by:
- Daily loop-diuretics administration for a minimum of 7 days before admission, or
- Insufficient decongestion observed in the preceding 24 hours (weight reduction \<500g or negative fluid balance \<1L) despite being treated with high-dose IV loop diuretic (equivalent to ≥120 mg IV furosemide within 24...
- Clinical signs of congestion, indicated by one or more of the following: pitting peripheral edema, ascites, elevated jugular venous pressure, or radiological/ultrasonic evidence of pulmonary congestion.
- Acute coronary syndrome
- Systolic blood pressure \<85 mmHg
- Use of renal replacement therapy or ultrafiltration in-hospital before study inclusion
- Treatment with acetazolamide or metolazone during the index hospitalization prior to randomization
- Known allergy to any of the used drugs
- Severe hypokalemia (\<2.5 mmol/l) or severe hyponatremia (\<125 mmol/l)
- Severe hepatic impairment or liver cirrhosis
- Known pregnancy
The study team makes the final eligibility decision.
Where it's taking place
- Hvidovre, Capital Region of Denmark, Denmark
- Copenhagen, Denmark
Compensation & support
A stipend or compensation may be offered.
Compensation likely.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hvidovre, Capital Region of Denmark, Denmark; Copenhagen, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.